MIRA INFORM REPORT
|
Report Date : |
02.07.2013 |
IDENTIFICATION DETAILS
|
Name : |
CHUGAI PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
15F, Nihombashi Mitsui Tower 2-1-1, Nihombashi-Muro-machi Chuo-Ku, 103-8324 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
08.03.1943 |
|
|
|
|
Legal Form : |
Public Subsidiary |
|
|
|
|
Line of Business : |
Manufacture of pharmaceutical preparations |
|
|
|
|
No. of Employees : |
6,836 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a
comparatively small defense allocation (1% of GDP) helped Japan develop a
technologically advanced economy. Two notable characteristics of the post-war
economy were the close interlocking structures of manufacturers, suppliers, and
distributors, known as keiretsu, and the guarantee of lifetime employment for a
substantial portion of the urban labor force. Both features are now eroding
under the dual pressures of global competition and domestic demographic change.
Japan's industrial sector is heavily dependent on imported raw materials and
fuels. A small agricultural sector is highly subsidized and protected, with
crop yields among the highest in the world. While self-sufficient in rice
production, Japan imports about 60% of its food on a caloric basis. For three
decades, overall real economic growth had been spectacular - a 10% average in
the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth
slowed markedly in the 1990s, averaging just 1.7%, largely because of the after
effects of inefficient investment and an asset price bubble in the late 1980s
that required a protracted period of time for firms to reduce excess debt,
capital, and labor. Modest economic growth continued after 2000, but the
economy has fallen into recession three times since 2008. A sharp downturn in
business investment and global demand for Japan's exports in late 2008 pushed
Japan into recession. Government stimulus spending helped the economy recover
in late 2009 and 2010, but the economy contracted again in 2011 as the massive
9.0 magnitude earthquake and the ensuing tsunami in March disrupted manufacturing.
The economy has largely recovered in the two years since the disaster, but
reconstruction in the Tohoku region has been uneven. Newly-elected Prime
Minister Shinzo ABE has declared the economy his government's top priority; he
has pledged to reconsider his predecessor's plan to permanently close nuclear
power plants and is pursuing an economic revitalization agenda of fiscal
stimulus and regulatory reform and has said he will press the Bank of Japan to
loosen monetary policy. Measured on a purchasing power parity (PPP) basis that
adjusts for price differences, Japan in 2012 stood as the fourth-largest
economy in the world after second-place China, which surpassed Japan in 2001,
and third-place India, which edged out Japan in 2012. The new government will continue
a longstanding debate on restructuring the economy and reining in Japan's huge
government debt, which exceeds 200% of GDP. Persistent deflation, reliance on
exports to drive growth, and an aging and shrinking population are other major
long-term challenges for the economy.
Source
: CIA
CHUGAI
PHARMACEUTICAL CO., LTD.
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business
Description
|
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical
company. The Company operates in two business segments. The Domestic segment is
engaged in the sale of pharmaceutical products manufactured by the Company
through its nationwide appointed stores. This segment is also involved in the
research, development, transportation and storage of pharmaceutical products,
as well as the provision of literature research services for pharmaceutical
information. The Overseas segment is engaged in the sale of its
pharmaceutical products in oversea markets, such as Germany, the United
Kingdom, France, Taiwan, China Mainland, Korea and the United States. This
segment is also involved in the provision of pharmaceutical academic
information, as well as the research, development and registration of
pharmaceutical products. As of December 31, 2012, the Company had 19
subsidiaries and one associated company. For the three months ended 31 March
2013, CHUGAI PHARMACEUTICAL CO., LTD. revenues increased less than 1% to
Y90.42B. Net income applicable to common stockholders decreased 17% to Y8.9B.
Revenues reflect other segment increase of 21% to Y4.93B, Japan (Country)
segment increase of less than 1% to Y78.13B, also reflect Switzerland
(Country) segment decrease of 9% to Y7.36B. |
Industry
|
Industry |
|
|
ANZSIC 2006: |
1841 - Human Pharmaceutical and Medicinal Product
Manufacturing |
|
NACE 2002: |
|
|
NAICS 2002: |
|
|
UK SIC 2003: |
|
|
UK SIC 2007: |
|
|
US SIC 1987: |
Key Executives
|
Significant Developments
|
Financial Summary
|
Stock Snapshot
|
1 - Profit &
Loss Item Exchange Rate: USD 1 = JPY 79.79749
2 - Balance Sheet Item Exchange Rate: USD 1 = JPY 85.87
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Strategic Initiatives report is created using technology to extract
meaningful insights from analyst reports about a company's strategic projects
and investments. More
about Strategic Initiatives
Strategic Initiatives
|
Partnerships |
|
|
The company’s current liabilities stood at JPY475,695m in 2012, as against
JPY419,427m in 2011, reflecting increase of 13.4%. On the other hand its
liabilities increased from JPY 68818 in 2012 to JPY91,633m in 2011 indicating
an increase of 33.1%.Strategic AlliancesAs part of its business strategy,
Chugai establishes and nourishes collaboration and agreements with other
companies to enhance its product portfolio and bring non-dilutive capital
into the company. In January 2013, the company entered into a collaboration
agreement with Debiopharm Group exclusive license to develop and
commercialize FF284. The agreement also includes a license to develop and
commercialize a companion diagnostic for FF284. |
|
|
On the other hand its liabilities increased from JPY 68818 in 2012 to
JPY91,633m in 2011 indicating an increase of 33.1%.Strategic AlliancesAs part
of its business strategy, Chugai establishes and nourishes collaboration and
agreements with other companies to enhance its product portfolio and bring
non-dilutive capital into the company. In January 2013, the company entered
into a collaboration agreement with Debiopharm Group exclusive license to
develop and commercialize FF284. The agreement also includes a license to
develop and commercialize a companion diagnostic for FF284. In November 2012,
Chugai entered into a co-development and co-marketing agreement with Nippon
Shinyaku Co. |
|
|
In March 2013, Chugai received approval for its subcutaneous injection
formulation of the humanized anti-human interleukin-6 (IL-6) receptor
monoclonal antibody, Actemra. In February 2013, Chugai filed an NDA for its
anti-cancer agent, Herceptin for additional dosage and administration for
postoperative adjuvant chemotherapy in breast cancer. In January 2013, the
company entered into a collaboration agreement with Debiopharm Group
exclusive license to develop and commercialize FF284. The agreement also
includes a license to develop and commercialize a companion diagnostic for
FF284. In the same month the company filed an NDA application for
antibody-drug conjugate trastuzumab emtansine for the treatment of
her2-positive metastatic or recurrent breast cancer.GlobalData uses a range
of research techniques to gather and verify its information and analysis. |
|
|
(Chugai) succeeded for the first time in the world in establishing
stable cell lines with the nature of colon cancer stem cells that are thought
to be involved in the recurrence/metastasis of cancer.Chugai discovered that
the cancer stem cells change to non-proliferative drug-resistant cells after
administration of an anticancer drug and restore their proliferative
properties when the administration of the anticancer drug is discontinued.
Chugai also found that an antibody that binds to a protein expressed on these
cancer stem cells can inhibit metastases when administered into mice that had
been injected with the cancer stem cells. This research was performed through
the collaboration of PharmaLogicals Research Pte. Ltd. (Singapore),
Forerunner Pharma Research Co. |
|
|
It has three products in Phase III clinical trials, namely, MRA
(Actemra) for Rheumatoid arthritis (new formulation: subcutaneous injection)
for which the US FDA has accepted the supplemental biologics application in
February 2012; and RG484 which has been filed for under a New Drug
Application for Osteoporosis. Its alliance with Roche led to significant
achievements in research and development programs. The company also shares
multiple agreements of product development such as small molecular
collaboration, biotechnology collaboration, concentration on ethical drug market,
oncology unit and the most important being the joint development program and
overseas filing of Actemra.Robust Operational BaseThe company has a robust
operational base consisting of manufacturing facilities, research and
development centers, and marketing abilities to cater to the needs of its
clients in an effective and efficient manner. The company has three core
research laboratories in Fuji-Gotemba, Shizuoka; Kamakura, Kanagawa; and
Ukima, Kita-ku. |
|
|
Chugai is a Japan-based pharmaceutical company carrying out manufacturing
and marketing pharmaceutical products in Japan and overseas. The company
utilizes leading technologies in biopharmaceutical and molecular targeted drug
discovery theraphy areas for the development of innovative drugs. The
company’s strategic alliance with Roche has led to significant internal
development and it has enhanced additional product development. However,
failure to comply with government regulatory standards, presence of counterfeit
drugs and uncertain R&D outcomes may hinder the company’s ability to earn
revenues and improve the financial condition of the company.
The company has a robust operational base consisting of manufacturing
facilities, research and development centers, and marketing abilities to cater
to the needs of its clients in an effective and efficient manner. The company
has three core research laboratories in Fuji-Gotemba, Shizuoka; Kamakura,
Kanagawa; and Ukima, Kita-ku. Fuji-Gotemba Laboratory undertakes research for
genomic antibody drug discovery research and low-molecular-weight drug in the
areas of bone/joint, renal/metabolic and immunological disease. The laboratory
also conducts property and product development research for existing products.
Kamakura Laboratory focuses on product and property research in the areas of
oncology and infectious diseases. The Pharmaceutical Technology and API Process
Development Division of Ukima Laboratory carry out investigation for
commercialization of new products. The company also utilizes the research
network of Roche Group for the global development of its research structure. In
July 2012, the company established a research subsidiary, Chugai Pharmabody
Research Pte. Ltd. to conduct antibody research, in Singapore. Chugai also
maintains three manufacturing facilities in Ukima, Fujieda, and Utsonomiya
operated under Chugai Pharma Manufacturing Co., Ltd. The Ukima plant carries
out manufacture biological drugs substances and injection formulations, and
packaging. The Fujieda plant manufactures products from synthetic drug
substances. The Utsonomiya manufactures drug substances for the biological and
antibody pharmaceuticals and formulation, and packaging. It has a total volume
of 80,000 liters. The company has its presence in both domestic and
international markets including Sapporo, Fukuoda Sendai, Tokyo, Takamatsu,
Yokohama, Osaka, Nagoya, Hiroshima and Kyoto in Japan, and US, Europe, China
and Taiwan. Such a strong operational base helped the company establish its
position in the pharmaceutical industry in the Philippines.
Chugai leverages its focused development activities to develop
pharmaceutical products for the treatment of cancer and various diseases including
renal diseases, bone and joint diseases, and transplant, immunologic and
infectious diseases. This enables the company to capture the immense potential
in the pharmaceuticals market. Chugai is an integrated pharmaceutical company
offering its products and services under two segments, Domestic and
International. The company’s product portfolio is divided into oncology; bone
and joint diseases; renal diseases; transplant, immunologic and infectious
diseases; and others. The products under oncology sub-segment include Avastin,
Herceptin, Rituxan, Xeloda, Neutrogin, Tarceva, Femara, and Kytril. The drugs
marketed and distributed for the treatment of bone and joint diseases are
Evista, Actemra, Suvenyl, Alfarol, Edirol, and other products. The products
offered in the renal diseases sub-segment are Epogin, Mircera, Oxarol, Renagel,
and other products. The transplant, immunological and infectious diseases
sub-segment markets and distributes Pegasys, Copegus, CellCept, Rocephin and
other products. The others sub-segment provides Sigmart and other products. The
company also offers Tamiflu in ordinary as well as government stockpile forms.
During 2011 and 2012, the company received approval for additional indications
from the Japanese Ministry of Health, Labor and Welfare (MHLW). These approvals
include Kytril for gastrointestinal symptoms (nausea and vomiting) associated
with antineoplastic agents administration and radiotherapy; Herceptin for
neo-adjuvant chemotherapy in early breast cancer that over expresses HER2 and
advanced or recurrent gastric cancer over expressing HER2, not amenable to
curative resection; Avastin for inoperable or recurrent breast cancer; pegasys
for improvement of viraemia associated with chronic active hepatitis B;
Cellcept for dosage and administration for pediatric patients for the
prophylaxis of organ rejection in patients receiving renal transplants; Tarceva
for pancreatic cancer, not amenable to curative resection; Pegasys and Copegus
for improvement of viraemia associated with compensated cirrhosis related to
hepatitis C; and Xeloda for advanced or recurrent gastric cancer over
expressing HER2, not amenable to curative resection ; and improvement of
viraemia associated with chronic hepatitis B. In October, the company’s ACTEMRA
received approval from the FDA for an additional indication of Rheumatoid
Arthritis; Avastin, for additional indication of ovarian cancer and recurrent
glioblastoma; Bactramin, for an additional indication of Pneumocystis pneumonia
and prevention of its development. Such wide product portfolio insulates the
company from fall in demand for any particular product line, thereby giving it
a balanced revenue platform.
Operating as a subsidiary of major player in pharmaceutical industry,
Hoffmann–La Roche, has enabled the company to increase the scope of its
business activities and successfully complement its market leadership position.
It has enabled Chugai to build a strong research capabilities and technology
platform in the area of biopharmaceuticals and small molecules. Chugai
implemented initiatives to enhance its operations in research and development,
safety management and sales production. Chugai’s merger with Roche has
significantly boosted its competitiveness in terms of research, development and
marketing. In research and development (R&D), the company successfully
utilized Roche’s global R&D infrastructure and participated in global
clinical studies partnering Genentech, Inc. of the US. The compounds
in-licensed from the Roche also have enhanced Chugai’s broad development
pipeline. The company also out-licensed a growing number of compounds to Roche.
In the area of marketing, the company’s access to the Roche’s efficient
global marketing network enabled Chugai to raise the international
competitiveness of its products. These initiatives produced significant
results. In April and August 2011, Chugai received approval for Actemra to be
used as a treatment for Systemic-onset juvenile idiopathic arthritis (SJIA)
from the US FDA and European Commission respectively. It has three products in
Phase III clinical trials, namely, MRA (Actemra) for Rheumatoid arthritis (new
formulation: subcutaneous injection) for which the US FDA has accepted the
supplemental biologics application in February 2012; and RG484 which has been
filed for under a New Drug Application for Osteoporosis. Its alliance with
Roche led to significant achievements in research and development programs. The
company also shares multiple agreements of product development such as small
molecular collaboration, biotechnology collaboration, concentration on ethical
drug market, oncology unit and the most important being the joint development
program and overseas filing of Actemra.
Geographical Concentration in Japan
Chugai's overwhelming dependence on Japanese markets to generate revenue
not only exposes it to the risks associated with limited geographical presence,
but also restrains its growth. Though the company has its presence in both
domestic and international markets including Japan, China, Taiwan, the US and
Europe; Chugai has been deriving most of its revenue from domestic operations
in Japan. For the fiscal year ended December 2012, the company reported
recorded more than 90% of the company’s total revenues. With increasing
demand for specialty pharmaceuticals worldwide, the company confining itself
only to the regions in South East Asia restricts its geographical presence and
limits its growth. Such concentration makes the company more vulnerable than
its competitors, which have greater geographical presence. Geographical
diversity offers opportunity for growth.
Chugai had relatively poor liquidity in fiscal years 2011 and 2012 as
compared to 2010. A decline in liquidity could affect the company’s growth in
the near future. The company could face difficulty in meeting its short term
obligations efficiently. Decline in assets that are easily convertible to cash,
produce less flexibility for the firm and increase investors’ risk.
Chugai’s current ratio declined from 7.08 times in 2010 to 6.09 times in
2011, which further declined to 5.19 times in 2012. The quick ratio decreased
to 4.0 times in 2012, as compared to 4.5 times in 2011 and the cash ratio also
declined to 2.3 times in 2012, as compared to 2.4 times in 2011. The company
reported a fall in all the liquidity ratios owing to more than proportionate
increase in current liabilities in comparison with current assets. The
company’s current liabilities stood at JPY475,695m in 2012, as against
JPY419,427m in 2011, reflecting increase of 13.4%. On the other hand its
liabilities increased from JPY 68818 in 2012 to JPY91,633m in 2011 indicating
an increase of 33.1%.
The company’s consistent focus on research and development activities
has helped it in the development of various pipeline projects of in house and
partnered therapeutics, which could provide ample of opportunities for the firm
to fuel its revenue growth in the long run. The company’s research and
development programs include oncology pipeline comprising RG1273, RG1415,
RG435, RG3502, GA101, GC33, RG340, AF802, WT4869, RG7167, RG7304, PA799,
RG3638, and MRA for pancreatic cancer, gastric cancer, breast cancer (adjuvant),
non-small cell lung cancer, aggressive Non Hodgkin’s lymphoma,
Myelosdisplastic syndrome glioblastoma, glioblastoma (relapsed) and breast
cancer; bone and joint diseases pipeline comprising RG484, and NRD101 for the
treatment of osteoporosis and entheospathy; autoimmune diseases pipeline
comprising MRA, SA237, and RG7415 for the treatment of rheumatoid arthritis and
systemic lupus; Diabetes Mellitus candidate CSG452; central nervous system
pipeline comprising RG1678, RG7090, RG1450 for the treatment of schizophrenia,
depressive disorder and Alzheimer’s disease; respiratory diseases candidate
RG3637 for the treatment of asthma; and development candidate CIM331 for the
treatment of atopic dermatitis. In February 2013, Chugai filed an NDA for its anti-cancer
agent, Herceptin for additional dosage and administration for postoperative
adjuvant chemotherapy in breast cancer. In January 2013, the company filed an
NDA application for antibody-drug conjugate trastuzumab emtansine for the
treatment of her2-positive metastatic or recurrent breast cancer. In October
2012, the company filed an application with the Japanese Ministry of Health,
Labour and Welfare for the approval of Avastin, its anticancer agent for an
additional indication of ovarian cancer. In September 2012, Chugai filed an
application for the approval of Avastin, for an additional indication of
recurrent glioblastoma. In August 2012, it filed an application with the
Japanese Ministry of Health, Labour and Welfare for the approval of Bactramin,
its synthetic antibacterial agent for an additional indication of Pneumocystis
pneumonia and prevention of its development. In May 2012, the company submitted
a New Drug Application for pertuzumab for the treatment of HER2-positive
metastatic or recurrent breast cancer. The successful development and
commercialization of these product candidates could significantly increase the
revenue of Chugai.
As part of its business strategy, Chugai establishes and nourishes
collaboration and agreements with other companies to enhance its product
portfolio and bring non-dilutive capital into the company. In January 2013, the
company entered into a collaboration agreement with Debiopharm Group exclusive
license to develop and commercialize FF284. The agreement also includes a
license to develop and commercialize a companion diagnostic for FF284. In
November 2012, Chugai entered into a co-development and co-marketing agreement
with Nippon Shinyaku Co., Ltd. to co-develop and co-market GA101 (obinutuzumab),
the first glycoengineered, type II anti-CD20 monoclonal antibody for the
treatment of non-Hodgkin’s lymphoma. In October 2012, the company entered
into a license agreement with Kowa Company and Sanofi K.K. to jointly develop
SGLT2 Inhibitor, CSG452 in Japan. Chugai also has strategic alliances with
other companies such as Forerunner Pharma Research Co., Ltd. (Tokyo), C&C
Research Laboratories (South Korea), and PharmaLogicals Research Pte. Ltd.
(Singapore) for novel drug discovery research.
The company could benefit from its focus on Oncology, as the company
aspires to establish itself as a key player in the oncology domain. Based on
the in-house research, global oncology therapeutics market increased was worth
nearly $33.3 billion in 2010, and is expected to witness moderate growth of
5.69% during 2010–2017, and is expected to touch $48.8 billion mark by 2017.
Within the oncology therapeutics market - breast, colorectal, lung, prostate,
and pancreatic cancers have the largest market in terms of the number of
patients diagnosed. According to the American Cancer Society, approximately
8,800 cases of Hodgkin lymphoma were diagnosed in the US during 2011, and an
estimated 1,300 people died of the disease. Approximately 2,000 additional
patients per year in the United States are diagnosed with sALCL, a type of
mature T-cell lymphoma that expresses the CD30 antigen. The factors such as
rapid uptake of targeted therapies in key cancer indications with increased
efficacy and reduced toxicity is expected to contribute to the growth. The
prevalence of cancer is expected to double in the coming two decades owing to
the steady increase in the elderly population. Thus, the growing potential
market will enhance the company’s future growth opportunities.
The company’s markets are characterized by intense competition,
evolving industry standards and business models. The demand for its products depends
on the competitive atmosphere, including the timely development and
introduction of new and competitive products and the company’s response to
downward pricing to sustain competition. Further western companies are
intensifying the competition in Japan. The International Conference on
Harmonization (ICH) had relaxed some of its regulations and allowed the Western
pharmaceutical companies to market products without carrying out separate
clinical trials in the Japanese market. Additionally, other foreign companies
are expanding their sales and marketing operations in Japan. Intense
competition in Japan, the company's largest geographical segment could increase
the threat to its market share. The competitors of the company have greater
experience, research and development capabilities, greater manufacturing,
marketing, financial, and managerial resources than the company. Factors
including changes in customer order patterns, changing incentive programs or
competitors’ new products can impact the company’s competitive ability.
Increased regulation of the drug market could impact the company’s
costs by increasing the time and cost of bringing drugs to market. The
company’s products, research and development activities and manufacturing
processes are subject to various local, state, federal, foreign and
transnational laws and regulations. In Japan, the MHLW regulates the
introduction of new products, besides the manufacturing, labeling and record
keeping procedures for such products. Receiving marketing approval for new
medical devices from the MHLW is time consuming and expensive. Products
distributed outside the Japan are also subject to government regulations, which
vary from country to country. The company has to comply with different
regulations governing product standards, packaging and labeling requirements,
import restrictions, tariff regulations and tax requirements. Non-compliance by
the company with applicable laws and regulations or failure to maintain, renew
or obtain necessary permits and licenses could have an adverse effect on the
company's results of operations and financial performance.
Adverse or inconclusive results from preclinical testing or clinical
trials may substantially delay or halt the development of the company's various
product candidates, consequently affecting its timeliness for profitability.
The outcome of clinical trials is always a subject of uncertainty. After the
discovery of a new compound, substantial amount of money and a great deal of
time are required to successfully launch a new product. Moreover, it may become
necessary to discontinue clinical development if the effectiveness of a drug is
not proven as initially expected, or if serious adverse effects arise. In addition,
pharmaceuticals are subject to legal restrictions in each country and
authorization from local regulatory authorities is a prerequisite for a product
launch in every country. It is difficult to accurately foresee when approvals
for a new product can be obtained.
|
CHUGAI
PHARMACEUTICAL CO., LTD. |
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
Parent |
Basel |
Switzerland |
Biotechnology and Drugs |
48,510.6 |
82,089 |
|
|
Subsidiary |
Basel |
Switzerland |
Biotechnology and Drugs |
48,403.0 |
82,089 |
|
|
Subsidiary |
Mannheim, Baden-Württemberg |
Germany |
Biotechnology and Drugs |
5,514.0 |
10,400 |
|
|
Subsidiary |
Ponce, PR |
United States |
Medical Equipment and Supplies |
|
222 |
|
|
Subsidiary |
Mannheim, Baden-Württemberg |
Germany |
Chemical Manufacturing |
18.0 |
111 |
|
|
Subsidiary |
Mannheim |
Germany |
Biotechnology and Drugs |
0.4 |
20 |
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Mexico, DF |
Mexico |
Biotechnology and Drugs |
|
2,000 |
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
787.9 |
1,300 |
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Biotechnology and Drugs |
1,391.4 |
1,294 |
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Sheringham |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Business Services |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Madrid |
Spain |
Biotechnology and Drugs |
845.1 |
1,137 |
|
|
Branch |
Madrid, Madrid |
Spain |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Heredia |
Costa Rica |
Biotechnology and Drugs |
|
1,000 |
|
|
Subsidiary |
Grenzach-Wyhlen |
Germany |
Biotechnology and Drugs |
|
1,000 |
|
|
Subsidiary |
Istanbul (Europe) |
Turkey |
Personal and Household Products |
|
820 |
|
|
Subsidiary |
Mississauga, ON |
Canada |
Biotechnology and Drugs |
104.9 |
700 |
|
|
Subsidiary |
Dee Why, NSW |
Australia |
Fish and Livestock |
|
590 |
|
|
Subsidiary |
Dee Why, NSW |
Australia |
Biotechnology and Drugs |
483.9 |
560 |
|
|
Subsidiary |
Laval, QC |
Canada |
Business Services |
1.1 |
500 |
|
|
Subsidiary |
Illovo |
South Africa |
Personal and Household Products |
|
450 |
|
|
Subsidiary |
Burgdorf |
Switzerland |
Medical Equipment and Supplies |
|
355 |
|
|
Subsidiary |
Almere |
Netherlands |
Medical Equipment and Supplies |
201.1 |
200 |
|
|
Subsidiary |
Wien |
Austria |
Medical Equipment and Supplies |
149.8 |
193 |
|
|
Subsidiary |
Fishers, IN |
United States |
Medical Equipment and Supplies |
1.3 |
150 |
|
|
Subsidiary |
Portsmouth, NH |
United States |
Medical Equipment and Supplies |
2.4 |
100 |
|
|
Subsidiary |
Kiel, Schleswig Holstein |
Germany |
Medical Equipment and Supplies |
|
20 |
|
|
Subsidiary |
Verona |
Italy |
Medical Equipment and Supplies |
|
12 |
|
|
Subsidiary |
Meylan, Cedex |
France |
Medical Equipment and Supplies |
|
|
|
|
Subsidiary |
Metro Manila |
Philippines |
Biotechnology and Drugs |
73.4 |
300 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
|
260 |
|
|
Subsidiary |
Buenos Aires |
Argentina |
Biotechnology and Drugs |
|
225 |
|
|
Subsidiary |
Budapest |
Hungary |
Business Services |
9.1 |
222 |
|
|
Subsidiary |
Bogotá DC |
Colombia |
Personal and Household Products |
301.7 |
200 |
|
|
Subsidiary |
Caracas |
Venezuela |
Personal and Household Products |
|
200 |
|
|
Subsidiary |
Prague |
Czech Republic |
Personal and Household Products |
|
200 |
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
200 |
|
|
Subsidiary |
Bangkok |
Thailand |
Personal and Household Products |
|
180 |
|
|
Subsidiary |
Taipei |
Taiwan |
Personal and Household Products |
|
175 |
|
|
Roche (Magyarország) Gyógyszer- és
Vegyianyagkereskedelmi Kft |
Subsidiary |
Budaörs |
Hungary |
Biotechnology and Drugs |
156.5 |
173 |
|
Subsidiary |
Maroussi |
Greece |
Personal and Household Products |
326.5 |
160 |
|
|
Subsidiary |
Reinach |
Switzerland |
Biotechnology and Drugs |
|
160 |
|
|
Subsidiary |
Vilvoorde |
Belgium |
Biotechnology and Drugs |
124.8 |
158 |
|
|
Subsidiary |
Wien |
Austria |
Personal and Household Products |
246.9 |
153 |
|
|
Subsidiary |
Bruxelles |
Belgium |
Personal and Household Products |
266.1 |
152 |
|
|
Subsidiary |
Woerden |
Netherlands |
Biotechnology and Drugs |
340.1 |
151 |
|
|
Subsidiary |
Sydney, NSW |
Australia |
Medical Equipment and Supplies |
36.2 |
150 |
|
|
Subsidiary |
Lima |
Peru |
Biotechnology and Drugs |
|
130 |
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
|
115 |
|
|
Subsidiary |
Montevideo |
Uruguay |
Biotechnology and Drugs |
|
107 |
|
|
Subsidiary |
Hvidovre |
Denmark |
Personal and Household Products |
131.4 |
104 |
|
|
Subsidiary |
Quito |
Ecuador |
Personal and Household Products |
|
90 |
|
|
Subsidiary |
Auckland, Penrose |
New Zealand |
Personal and Household Products |
12.1 |
85 |
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
115.0 |
67 |
|
|
Subsidiary |
Kulmbach, Bayern |
Germany |
Biotechnology and Drugs |
|
67 |
|
|
Subsidiary |
Oslo |
Norway |
Personal and Household Products |
82.7 |
60 |
|
|
Subsidiary |
Singapore |
Singapore |
Personal and Household Products |
|
50 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
Newbury |
United Kingdom |
Biotechnology and Drugs |
|
35 |
|
|
Subsidiary |
Santo Domingo, D. N. |
Dominican Republic |
Chemical Manufacturing |
|
20 |
|
|
Subsidiary |
Paramus, NJ |
United States |
Healthcare Facilities |
0.6 |
13 |
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
10 |
|
|
Subsidiary |
Santiago |
Chile |
Biotechnology and Drugs |
|
10 |
|
|
Subsidiary |
Panama |
Panama |
Biotechnology and Drugs |
|
8 |
|
|
Subsidiary |
Managua |
Nicaragua |
Personal and Household Products |
|
5 |
|
|
Subsidiary |
Guatemala |
Guatemala |
Biotechnology and Drugs |
|
|
|
|
Joint Venture |
Wuxi, Jiangsu |
China |
Chemical Manufacturing |
|
|
|
|
Subsidiary |
San Salvador |
El Salvador |
Personal and Household Products |
|
|
|
|
Subsidiary |
Chatuchak, Bangkok |
Thailand |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Panama City, Panama |
Panama |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Petah Tiqwa |
Israel |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Guatemala |
Guatemala |
Personal and Household Products |
|
|
|
|
Productos Roche, S.A. De C.V. |
Subsidiary |
|
|
|
|
|
|
Subsidiary |
Basel |
Switzerland |
Biotechnology and Drugs |
10,922.0 |
28,517 |
|
|
Subsidiary |
Rotkreuz |
Switzerland |
Biotechnology and Drugs |
|
20,000 |
|
|
Subsidiary |
South San Francisco, CA |
United States |
Biotechnology and Drugs |
13,418.0 |
11,000 |
|
|
Subsidiary |
Houston, TX |
United States |
Biotechnology and Drugs |
|
197 |
|
|
Branch |
Piscataway, NJ |
United States |
Retail (Drugs) |
3.1 |
10 |
|
|
Branch |
Oceanside, CA |
United States |
Personal and Household Products |
21.6 |
8 |
|
|
Branch |
Newark, DE |
United States |
Healthcare Facilities |
1.4 |
7 |
|
|
Branch |
Seaford, DE |
United States |
Healthcare Facilities |
1.4 |
7 |
|
|
Branch |
Aurora, NC |
United States |
Healthcare Facilities |
1.2 |
7 |
|
|
Branch |
Dover, DE |
United States |
Healthcare Facilities |
1.0 |
5 |
|
|
Branch |
Greensburg, IN |
United States |
Healthcare Facilities |
0.9 |
5 |
|
|
Branch |
Durham, NC |
United States |
Healthcare Facilities |
0.9 |
5 |
|
|
Branch |
Eaton, OH |
United States |
Healthcare Facilities |
0.9 |
5 |
|
|
Branch |
Wichita, KS |
United States |
Healthcare Facilities |
0.8 |
5 |
|
|
Branch |
Totowa, NJ |
United States |
Printing Services |
0.7 |
4 |
|
|
Branch |
Lewisville, TX |
United States |
Healthcare Facilities |
0.6 |
4 |
|
|
Branch |
Rockledge, FL |
United States |
Biotechnology and Drugs |
|
4 |
|
|
Branch |
Sidney, OH |
United States |
Biotechnology and Drugs |
|
4 |
|
|
Branch |
New York, NY |
United States |
Personal and Household Products |
7.7 |
3 |
|
|
Branch |
Providence, RI |
United States |
Personal and Household Products |
7.2 |
3 |
|
|
Subsidiary |
Smyrna, DE |
United States |
Healthcare Facilities |
0.6 |
3 |
|
|
Branch |
Camden, OH |
United States |
Healthcare Facilities |
0.5 |
3 |
|
|
Branch |
Moorefield, WV |
United States |
Healthcare Facilities |
0.5 |
3 |
|
|
Branch |
Northfork, WV |
United States |
Healthcare Facilities |
0.5 |
3 |
|
|
Branch |
Metropolis, IL |
United States |
Biotechnology and Drugs |
|
3 |
|
|
Branch |
Middletown, DE |
United States |
Biotechnology and Drugs |
|
3 |
|
|
Branch |
Middletown, DE |
United States |
Biotechnology and Drugs |
|
3 |
|
|
Subsidiary |
O Porriño, Pontevedra |
Spain |
Medical Equipment and Supplies |
69.2 |
1 |
|
|
Subsidiary |
Chuo-Ku |
Japan |
Biotechnology and Drugs |
4,902.7 |
6,836 |
|
|
Subsidiary |
London |
United Kingdom |
Business Services |
169.6 |
192 |
|
|
Subsidiary |
London |
United Kingdom |
Retail (Specialty) |
15.0 |
36 |
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
124.5 |
74 |
|
|
Subsidiary |
Antony, Cedex |
France |
Biotechnology and Drugs |
115.8 |
17 |
|
|
Joint Venture |
Hwasun, Kyunggi Do |
Korea, Republic of |
Biotechnology and Drugs |
|
60 |
|
|
Subsidiary |
Taipei |
Taiwan |
Biotechnology and Drugs |
|
50 |
|
|
Subsidiary |
London |
United Kingdom |
Business Services |
10.2 |
33 |
|
|
Subsidiary |
Berkeley Heights, NJ |
United States |
Biotechnology and Drugs |
|
20 |
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
20 |
|
|
Subsidiary |
Tokyo |
Japan |
Business Services |
|
13 |
|
|
Subsidiary |
New York, NY |
United States |
Personal and Household Products |
|
2 |
|
|
Subsidiary |
Kita-Ku, Tokyo |
Japan |
Biotechnology and Drugs |
1,309.3 |
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Investment Services |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Business Services |
|
|
|
|
Subsidiary |
Kazo, Saitama |
Japan |
Personal and Household Products |
|
|
|
|
Subsidiary |
Gotemba, Shizuoka |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Business Services |
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Business Services |
|
|
|
|
Facility |
Tokyo |
Japan |
Biotechnology and Drugs |
|
|
|
|
Facility |
Fujieda, Shizuoka |
Japan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Beijing |
China |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Nutley, NJ |
United States |
Biotechnology and Drugs |
|
6,600 |
|
|
Subsidiary |
Palo Alto, CA |
United States |
Business Services |
|
1,300 |
|
|
Subsidiary |
Boulder, CO |
United States |
Biotechnology and Drugs |
267.6 |
325 |
|
|
Subsidiary |
Florence, SC |
United States |
Biotechnology and Drugs |
32.0 |
300 |
|
|
Subsidiary |
Indianapolis, IN |
United States |
Scientific and Technical Instruments |
42,041.0 |
3,500 |
|
|
Branch |
Fishers, IN |
United States |
Medical Equipment and Supplies |
330.9 |
1,000 |
|
|
Unit |
Pleasanton, CA |
United States |
Biotechnology and Drugs |
|
1,000 |
|
|
Unit |
Branchburg, NJ |
United States |
Biotechnology and Drugs |
|
700 |
|
|
Unit |
Ponce, PR |
United States |
Biotechnology and Drugs |
1.0 |
230 |
|
|
Branch |
Washington, DC |
United States |
Healthcare Facilities |
1.2 |
5 |
|
|
Branch |
Carmel, IN |
United States |
Personal Services |
|
5 |
|
|
Division |
Indianapolis, IN |
United States |
Business Services |
|
|
|
|
Subsidiary |
Madison, WI |
United States |
Biotechnology and Drugs |
|
135 |
|
|
Subsidiary |
Waldkraiburg |
Germany |
Business Services |
|
8 |
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
1,800 |
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Business Services |
|
1,604 |
|
|
Subsidiary |
Tucson, AZ |
United States |
Healthcare Facilities |
238.2 |
1,500 |
|
|
Subsidiary |
Illkirch-Graffenstaden |
France |
Medical Equipment and Supplies |
|
350 |
|
|
Subsidiary |
Mountain View, CA |
United States |
Biotechnology and Drugs |
|
7 |
|
|
Subsidiary |
México, D.F. |
Mexico |
Biotechnology and Drugs |
675.1 |
1,415 |
|
|
Subsidiary |
Boulogne Billancourt |
France |
Personal and Household Products |
1,942.5 |
1,277 |
|
|
Subsidiary |
Grenzach-Wyhlen, Baden-Württemberg |
Germany |
Biotechnology and Drugs |
1,924.1 |
1,155 |
|
|
Subsidiary |
Meylan |
France |
Personal and Household Products |
524.0 |
749 |
|
|
Subsidiary |
Burgess Hill |
United Kingdom |
Business Services |
392.5 |
512 |
|
|
Subsidiary |
Burgess Hill |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Welwyn Garden City |
United Kingdom |
Medical Equipment and Supplies |
|
|
|
|
Subsidiary |
Branchburg, NJ |
United States |
Medical Equipment and Supplies |
142.8 |
500 |
|
|
Subsidiary |
Tokyo |
Japan |
Medical Equipment and Supplies |
|
500 |
|
|
Subsidiary |
Monza |
Italy |
Medical Equipment and Supplies |
613.8 |
499 |
|
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
321.2 |
400 |
|
|
Subsidiary |
Ricardo Rojas, Buenos Aires |
Argentina |
Biotechnology and Drugs |
273.5 |
400 |
|
|
Subsidiary |
Ciudad De Mexico, Distrito Federal |
Mexico |
Biotechnology and Drugs |
240.4 |
300 |
|
|
Subsidiary |
Laval, QC |
Canada |
Scientific and Technical Instruments |
217.7 |
250 |
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
115.0 |
234 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Personal and Household Products |
153.2 |
223 |
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
217.9 |
200 |
|
|
Subsidiary |
Branford, CT |
United States |
Biotechnology and Drugs |
|
180 |
|
|
Subsidiary |
Amadora, Lisboa |
Portugal |
Biotechnology and Drugs |
219.5 |
175 |
|
|
Subsidiary |
Lima |
Peru |
Personal and Household Products |
|
170 |
|
|
Subsidiary |
Lima, Lima |
Peru |
Medical Equipment and Supplies |
|
167 |
|
|
Subsidiary |
Casablanca |
Morocco |
Medical Equipment and Supplies |
|
150 |
|
|
Subsidiary |
Stockholm |
Sweden |
Personal and Household Products |
158.8 |
137 |
|
|
Subsidiary |
Graz |
Austria |
Medical Equipment and Supplies |
71.2 |
130 |
|
|
Subsidiary |
Singapore |
Singapore |
Medical Equipment and Supplies |
29.8 |
130 |
|
|
The Resident Representative Office Of Hoffmann-La
Roche Ltd In Ho Chi Minh City |
Subsidiary |
Ho Chi Minh, Ho Chi Minh City |
Viet Nam |
Personal and Household Products |
|
130 |
|
Subsidiary |
Athens |
Greece |
Business Services |
90.7 |
125 |
|
|
Subsidiary |
Hvidovre |
Denmark |
Personal and Household Products |
59.6 |
122 |
|
|
Subsidiary |
Sofia |
Bulgaria |
Biotechnology and Drugs |
65.4 |
107 |
|
|
Subsidiary |
Espoo |
Finland |
Personal and Household Products |
99.8 |
100 |
|
|
Subsidiary |
Amadora |
Portugal |
Biotechnology and Drugs |
68.5 |
100 |
|
|
Subsidiary |
Bromma |
Sweden |
Medical Equipment and Supplies |
66.1 |
100 |
|
|
Subsidiary |
Causeway Bay |
Hong Kong |
Biotechnology and Drugs |
|
100 |
|
|
Subsidiary |
Schlieren |
Switzerland |
Biotechnology and Drugs |
|
80 |
|
|
Subsidiary |
Ljubljana |
Slovenia |
Biotechnology and Drugs |
|
75 |
|
|
Subsidiary |
Ciudad De Mexico, Distrito Federal |
Mexico |
Biotechnology and Drugs |
|
75 |
|
|
Subsidiary |
Oslo |
Norway |
Medical Equipment and Supplies |
68.2 |
74 |
|
|
Subsidiary |
Auckland |
New Zealand |
Medical Equipment and Supplies |
1.6 |
70 |
|
|
Subsidiary |
Espoo |
Finland |
Medical Equipment and Supplies |
50.7 |
62 |
|
|
Subsidiary |
Frankfurt Am Main, Hessen |
Germany |
Personal and Household Products |
|
62 |
|
|
Subsidiary |
Kwai Chung |
Hong Kong |
Medical Equipment and Supplies |
6.4 |
60 |
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
|
60 |
|
|
Subsidiary |
Belgrade |
Serbia |
Biotechnology and Drugs |
|
54 |
|
|
Subsidiary |
Ayr, ON |
Canada |
Chemical Manufacturing |
31.0 |
35 |
|
|
Subsidiary |
Riga |
Latvia |
Biotechnology and Drugs |
68.5 |
30 |
|
|
Subsidiary |
Woerden, Utrecht |
Netherlands |
Investment Services |
|
10 |
|
|
Subsidiary |
Monza, MI |
Italy |
Biotechnology and Drugs |
1,413.9 |
1,091 |
|
|
Subsidiary |
Grenzach-Wyhlen, Baden-Württemberg |
Germany |
Biotechnology and Drugs |
|
5 |
|
|
Subsidiary |
Mannheim, Baden-Württemberg |
Germany |
Personal and Household Products |
1,528.0 |
1,340 |
|
|
Subsidiary |
Waiblingen, Baden-Württemberg |
Germany |
Medical Equipment and Supplies |
|
200 |
|
|
Subsidiary |
Berlin, Berlin |
Germany |
Biotechnology and Drugs |
6.9 |
90 |
|
|
Subsidiary |
Grenzach-Wyhlen, Baden-Württemberg |
Germany |
Consumer Financial Services |
|
|
|
|
Subsidiary |
Woerden, Utrecht |
Netherlands |
Miscellaneous Financial Services |
|
|
|
|
Subsidiary |
Carmel, IN |
United States |
Biotechnology and Drugs |
1.0 |
9 |
|
|
Subsidiary |
Montvale, NJ |
United States |
Biotechnology and Drugs |
12.0 |
8 |
|
|
Subsidiary |
Mumbai |
India |
Business Services |
85.8 |
|
|
|
Subsidiary |
Kuala Lumpur |
Malaysia |
Biotechnology and Drugs |
79.4 |
|
|
|
Subsidiary |
Bielefeld |
Germany |
Biotechnology and Drugs |
14.0 |
|
|
|
Subsidiary |
Slough |
United Kingdom |
Biotechnology and Drugs |
0.0 |
|
|
|
Subsidiary |
Toronto, ON |
Canada |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Jakarta |
Indonesia |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Karachi, Karachi |
Pakistan |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Casablanca |
Morocco |
Business Services |
|
|
|
|
Subsidiary |
Warsaw |
Poland |
Business Services |
|
|
|
|
Subsidiary |
Halifax, NS |
Canada |
Nonclassifiable Industries |
|
|
|
|
Subsidiary |
Hamilton |
Bermuda |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Vilnius |
Lithuania |
Personal and Household Products |
|
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
|
|
|
|
Subsidiary |
Kiev |
Ukraine |
Personal and Household Products |
|
|
|
|
Subsidiary |
Indianapolis, IN |
United States |
Business Services |
|
|
|
|
Subsidiary |
Moscow |
Russian Federation |
Biotechnology and Drugs |
|
|
|
Competitors
Report
|
Executives Report
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.797487 |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
|
Auditor |
KPMG AZSA LLC |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
4,702.3 |
4,562.5 |
4,278.0 |
4,476.7 |
3,162.0 |
|
Revenue |
4,702.3 |
4,562.5 |
4,278.0 |
4,476.7 |
3,162.0 |
|
Other Revenue |
200.3 |
124.2 |
45.0 |
105.1 |
- |
|
Other Revenue, Total |
200.3 |
124.2 |
45.0 |
105.1 |
- |
|
Total Revenue |
4,902.7 |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
|
|
|
|
|
|
|
|
Cost of Revenue |
2,101.9 |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
|
Cost of Revenue, Total |
2,101.9 |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
|
Gross Profit |
2,600.4 |
2,586.2 |
2,427.9 |
2,416.7 |
1,933.4 |
|
|
|
|
|
|
|
|
Selling/General/Administrative Expense |
504.5 |
554.9 |
485.6 |
478.2 |
441.9 |
|
Labor & Related Expense |
469.5 |
470.4 |
428.4 |
391.5 |
328.0 |
|
Advertising Expense |
178.5 |
200.8 |
181.1 |
178.8 |
150.1 |
|
Total Selling/General/Administrative Expenses |
1,152.6 |
1,226.1 |
1,095.2 |
1,048.6 |
919.9 |
|
Research & Development |
690.6 |
700.8 |
623.1 |
590.8 |
514.8 |
|
Restructuring Charge |
0.1 |
0.9 |
-5.5 |
13.1 |
5.2 |
|
Impairment-Assets Held for Use |
5.9 |
12.5 |
4.4 |
2.5 |
10.7 |
|
Impairment-Assets Held for Sale |
-16.7 |
3.2 |
31.5 |
-78.1 |
13.2 |
|
Other Unusual Expense (Income) |
-0.6 |
75.3 |
-0.6 |
-0.3 |
-65.1 |
|
Unusual Expense (Income) |
-11.3 |
91.9 |
29.8 |
-62.8 |
-36.1 |
|
Other Operating Expense |
0.0 |
- |
- |
- |
- |
|
Other Operating Expenses, Total |
0.0 |
- |
- |
- |
- |
|
Total Operating Expense |
3,933.8 |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
|
|
|
|
|
|
|
|
Operating Income |
968.9 |
691.4 |
724.7 |
945.2 |
534.8 |
|
|
|
|
|
|
|
|
Interest Expense -
Non-Operating |
-0.1 |
-0.1 |
0.0 |
-0.2 |
-1.3 |
|
Interest Expense, Net Non-Operating |
-0.1 |
-0.1 |
0.0 |
-0.2 |
-1.3 |
|
Interest Income -
Non-Operating |
4.5 |
4.8 |
3.6 |
6.9 |
15.6 |
|
Investment Income -
Non-Operating |
-34.3 |
12.9 |
12.5 |
-9.8 |
67.8 |
|
Interest/Investment Income - Non-Operating |
-29.8 |
17.7 |
16.2 |
-2.9 |
83.4 |
|
Interest Income (Expense) - Net Non-Operating Total |
-29.9 |
17.6 |
16.1 |
-3.1 |
82.1 |
|
Gain (Loss) on Sale of Assets |
0.0 |
-0.1 |
0.2 |
2.8 |
-14.5 |
|
Other Non-Operating Income (Expense) |
4.9 |
8.0 |
7.2 |
10.3 |
8.0 |
|
Other, Net |
4.9 |
8.0 |
7.2 |
10.3 |
8.0 |
|
Income Before Tax |
943.9 |
716.9 |
748.3 |
955.1 |
610.4 |
|
|
|
|
|
|
|
|
Total Income Tax |
330.0 |
261.7 |
263.1 |
333.1 |
215.4 |
|
Income After Tax |
613.9 |
455.2 |
485.2 |
622.1 |
394.9 |
|
|
|
|
|
|
|
|
Minority Interest |
-9.8 |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
|
Net Income Before Extraord Items |
604.1 |
442.2 |
472.0 |
605.0 |
379.8 |
|
Net Income |
604.1 |
442.2 |
472.0 |
605.0 |
379.8 |
|
|
|
|
|
|
|
|
Miscellaneous Earnings Adjustment |
- |
-0.1 |
0.0 |
-0.1 |
0.0 |
|
Total Adjustments to Net Income |
- |
-0.1 |
0.0 |
-0.1 |
0.0 |
|
Income Available to Common Excl Extraord Items |
604.1 |
442.1 |
472.0 |
604.9 |
379.7 |
|
|
|
|
|
|
|
|
Income Available to Common Incl Extraord Items |
604.1 |
442.1 |
472.0 |
604.9 |
379.7 |
|
|
|
|
|
|
|
|
Basic/Primary Weighted Average Shares |
544.2 |
544.2 |
544.2 |
544.5 |
544.8 |
|
Basic EPS Excl Extraord Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Basic/Primary EPS Incl Extraord Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Dilution Adjustment |
- |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
604.1 |
442.1 |
472.0 |
604.9 |
379.8 |
|
Diluted Weighted Average Shares |
544.5 |
544.4 |
544.3 |
544.6 |
545.0 |
|
Diluted EPS Excl Extraord Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Diluted EPS Incl Extraord Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Dividends per Share - Common Stock Primary Issue |
0.50 |
0.50 |
0.46 |
0.43 |
0.33 |
|
Gross Dividends - Common Stock |
272.8 |
273.1 |
247.9 |
232.6 |
179.1 |
|
Interest Expense, Supplemental |
0.1 |
0.1 |
0.0 |
0.2 |
1.3 |
|
Depreciation, Supplemental |
192.1 |
199.5 |
204.8 |
208.3 |
194.2 |
|
Total Special Items |
-11.3 |
92.0 |
29.6 |
-65.6 |
-21.6 |
|
Normalized Income Before Tax |
932.6 |
808.9 |
777.9 |
889.6 |
588.8 |
|
|
|
|
|
|
|
|
Effect of Special Items on Income Taxes |
-3.9 |
33.6 |
10.4 |
-22.9 |
-7.6 |
|
Inc Tax Ex Impact of Sp Items |
326.0 |
295.3 |
273.5 |
310.2 |
207.8 |
|
Normalized Income After Tax |
606.6 |
513.7 |
504.4 |
579.4 |
381.0 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
596.7 |
500.5 |
491.2 |
562.2 |
365.8 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.10 |
0.92 |
0.90 |
1.03 |
0.67 |
|
Diluted Normalized EPS |
1.10 |
0.92 |
0.90 |
1.03 |
0.67 |
|
Advertising Expense, Supplemental |
178.5 |
200.8 |
181.1 |
178.8 |
150.1 |
|
Research & Development Exp, Supplemental |
690.6 |
700.8 |
623.1 |
590.8 |
514.8 |
|
Reported Operating Profit |
957.6 |
783.3 |
754.5 |
882.4 |
498.7 |
|
Reported Ordinary Profit |
945.0 |
797.8 |
741.4 |
965.6 |
553.8 |
|
Normalized EBIT |
957.6 |
783.4 |
754.5 |
882.5 |
498.7 |
|
Normalized EBITDA |
1,149.7 |
982.9 |
959.4 |
1,090.8 |
692.9 |
|
Current Tax - Total |
287.5 |
- |
- |
- |
- |
|
Current Tax - Total |
287.5 |
- |
- |
- |
- |
|
Deferred Tax - Total |
42.4 |
- |
- |
- |
- |
|
Deferred Tax - Total |
42.4 |
- |
- |
- |
- |
|
Income Tax - Total |
329.9 |
- |
- |
- |
- |
|
Interest Cost - Domestic |
18.6 |
18.5 |
16.6 |
15.0 |
13.3 |
|
Service Cost - Domestic |
35.0 |
33.7 |
30.6 |
27.5 |
25.1 |
|
Prior Service Cost - Domestic |
-4.0 |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
|
Expected Return on Assets - Domestic |
-17.4 |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
|
Actuarial Gains and Losses - Domestic |
9.4 |
7.3 |
10.2 |
12.2 |
-1.3 |
|
Transition Costs - Domestic |
- |
- |
- |
- |
1.0 |
|
Other Pension, Net - Domestic |
0.0 |
0.3 |
- |
0.6 |
- |
|
Domestic Pension Plan Expense |
41.5 |
37.4 |
38.0 |
36.5 |
19.0 |
|
Defined Contribution Expense - Domestic |
10.8 |
10.6 |
9.5 |
8.6 |
7.3 |
|
Total Pension Expense |
52.3 |
48.0 |
47.5 |
45.1 |
26.3 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
0.80% |
1.30% |
0.60% |
0.80% |
0.70% |
|
Total Plan Interest Cost |
18.6 |
18.5 |
16.6 |
15.0 |
13.3 |
|
Total Plan Service Cost |
35.0 |
33.7 |
30.6 |
27.5 |
25.1 |
|
Total Plan Expected Return |
-17.4 |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
|
Total Plan Other Expense |
0.0 |
0.3 |
- |
0.6 |
- |
|
|
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
85.870003 |
76.94 |
81.105 |
93.095 |
90.65 |
|
Auditor |
KPMG AZSA LLC |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash & Equivalents |
1,291.9 |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
|
Short Term Investments |
1,176.1 |
792.8 |
736.1 |
560.3 |
603.6 |
|
Cash and Short Term Investments |
2,468.0 |
2,185.6 |
1,675.7 |
1,709.4 |
1,384.3 |
|
Accounts Receivable -
Trade, Gross |
1,397.4 |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
|
Provision for Doubtful
Accounts |
-0.1 |
0.0 |
-0.1 |
-0.4 |
-0.7 |
|
Trade Accounts Receivable - Net |
1,397.3 |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
|
Total Receivables, Net |
1,397.3 |
1,441.5 |
1,398.0 |
1,305.9 |
1,195.8 |
|
Inventories - Finished Goods |
919.4 |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
|
Inventories - Work In Progress |
4.0 |
0.3 |
0.2 |
0.1 |
0.6 |
|
Inventories - Raw Materials |
344.6 |
230.3 |
190.1 |
224.8 |
187.4 |
|
Total Inventory |
1,268.1 |
1,364.5 |
1,293.2 |
995.1 |
868.6 |
|
Deferred Income Tax - Current Asset |
235.4 |
295.6 |
245.7 |
226.2 |
240.9 |
|
Other Current Assets |
170.9 |
164.2 |
153.2 |
181.5 |
109.2 |
|
Other Current Assets, Total |
406.3 |
459.8 |
398.9 |
407.7 |
350.1 |
|
Total Current Assets |
5,539.7 |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
|
|
|
|
|
|
|
|
Buildings |
1,458.6 |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
|
Land/Improvements |
118.2 |
132.3 |
122.0 |
106.3 |
109.6 |
|
Machinery/Equipment |
1,546.2 |
1,643.3 |
1,572.2 |
1,306.4 |
1,224.9 |
|
Construction in
Progress |
5.5 |
35.3 |
24.8 |
16.4 |
60.5 |
|
Other
Property/Plant/Equipment |
2.2 |
0.8 |
0.6 |
0.2 |
0.0 |
|
Property/Plant/Equipment - Gross |
3,130.8 |
3,371.5 |
3,271.5 |
2,763.0 |
2,751.5 |
|
Accumulated Depreciation |
-2,172.7 |
-2,293.6 |
-2,187.0 |
-1,756.9 |
-1,666.7 |
|
Property/Plant/Equipment - Net |
958.1 |
1,077.9 |
1,084.4 |
1,006.1 |
1,084.9 |
|
Intangibles, Net |
19.8 |
25.5 |
29.1 |
34.8 |
34.3 |
|
LT Investment - Affiliate Companies |
0.7 |
0.8 |
0.7 |
- |
- |
|
LT Investments - Other |
71.5 |
82.8 |
92.8 |
103.7 |
158.7 |
|
Long Term Investments |
72.2 |
83.6 |
93.5 |
103.7 |
158.7 |
|
Note Receivable - Long Term |
1.5 |
0.1 |
0.2 |
0.3 |
0.5 |
|
Deferred Income Tax - Long Term Asset |
149.3 |
182.4 |
184.2 |
156.8 |
134.6 |
|
Other Long Term Assets |
103.6 |
112.9 |
106.2 |
86.5 |
67.1 |
|
Other Long Term Assets, Total |
253.0 |
295.2 |
290.4 |
243.3 |
201.6 |
|
Total Assets |
6,844.3 |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
|
|
|
|
|
|
|
|
Accounts Payable |
485.9 |
225.5 |
240.3 |
368.0 |
317.3 |
|
Accrued Expenses |
354.1 |
335.9 |
265.8 |
354.1 |
281.6 |
|
Notes Payable/Short Term Debt |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|
Current Portion - Long Term Debt/Capital Leases |
- |
- |
- |
0.1 |
0.0 |
|
Income Taxes Payable |
138.0 |
184.0 |
45.4 |
237.8 |
125.5 |
|
Other Payables |
58.5 |
102.5 |
73.2 |
70.9 |
77.8 |
|
Deferred Income Tax - Current Liability |
- |
- |
- |
- |
0.0 |
|
Other Current Liabilities |
30.7 |
46.6 |
48.4 |
48.4 |
63.9 |
|
Other Current liabilities, Total |
227.1 |
333.1 |
166.9 |
357.1 |
267.3 |
|
Total Current Liabilities |
1,067.1 |
894.4 |
672.9 |
1,079.3 |
866.2 |
|
|
|
|
|
|
|
|
Capital Lease Obligations |
- |
- |
- |
0.1 |
0.0 |
|
Total Long Term Debt |
0.0 |
0.0 |
0.0 |
0.1 |
0.0 |
|
Total Debt |
0.0 |
0.0 |
0.0 |
0.2 |
0.0 |
|
|
|
|
|
|
|
|
Deferred Income Tax - LT Liability |
1.3 |
1.4 |
0.0 |
0.0 |
0.0 |
|
Deferred Income Tax |
1.3 |
1.4 |
0.0 |
0.0 |
0.0 |
|
Minority Interest |
14.0 |
15.7 |
16.8 |
19.2 |
18.2 |
|
Reserves |
2.0 |
2.3 |
0.0 |
- |
- |
|
Pension Benefits - Underfunded |
43.0 |
43.2 |
41.0 |
37.3 |
31.5 |
|
Other Long Term Liabilities |
23.6 |
25.7 |
8.8 |
20.4 |
0.8 |
|
Other Liabilities, Total |
68.7 |
71.3 |
49.8 |
57.7 |
32.3 |
|
Total Liabilities |
1,151.1 |
982.7 |
739.5 |
1,156.3 |
916.7 |
|
|
|
|
|
|
|
|
Common Stock |
849.7 |
948.3 |
899.6 |
783.8 |
804.9 |
|
Common Stock |
849.7 |
948.3 |
899.6 |
783.8 |
804.9 |
|
Additional Paid-In Capital |
1,095.1 |
1,219.5 |
1,153.9 |
1,002.7 |
1,027.5 |
|
Retained Earnings (Accumulated Deficit) |
4,261.8 |
4,412.2 |
4,039.7 |
3,308.3 |
2,989.6 |
|
Treasury Stock - Common |
-420.8 |
-471.3 |
-447.0 |
-389.6 |
-388.0 |
|
Unrealized Gain (Loss) |
19.1 |
10.9 |
16.5 |
17.6 |
14.9 |
|
Translation Adjustment |
-113.2 |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
|
Other Equity |
0.0 |
- |
- |
- |
- |
|
Other Comprehensive Income |
1.4 |
- |
- |
- |
- |
|
Other Equity, Total |
-111.8 |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
|
Total Equity |
5,693.2 |
5,950.9 |
5,524.1 |
4,650.0 |
4,362.0 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders’ Equity |
6,844.3 |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.6 |
|
|
|
|
|
|
|
|
Shares Outstanding - Common Stock Primary
Issue |
544.2 |
544.2 |
544.2 |
544.2 |
544.8 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.2 |
544.8 |
|
Treasury Shares - Common Stock Primary Issue |
15.4 |
15.5 |
15.5 |
15.5 |
14.9 |
|
Employees |
6,836 |
6,779 |
6,709 |
6,485 |
6,383 |
|
Number of Common Shareholders |
43,909 |
49,522 |
50,418 |
55,513 |
44,372 |
|
Total Long Term Debt, Supplemental |
1.8 |
2.0 |
1.8 |
1.6 |
- |
|
Long Term Debt Maturing within 1 Year |
1.8 |
- |
- |
- |
- |
|
Long Term Debt Matur. in Year 6 & Beyond |
0.0 |
2.0 |
1.8 |
1.6 |
- |
|
Total Capital Leases, Supplemental |
1.2 |
0.5 |
0.4 |
0.2 |
- |
|
Capital Lease Payments Due in Year 1 |
0.5 |
0.3 |
0.2 |
0.1 |
- |
|
Capital Lease Payments Due in Year 2 |
0.4 |
0.2 |
0.1 |
0.0 |
- |
|
Capital Lease Payments Due in Year 3 |
0.2 |
0.0 |
0.0 |
0.0 |
- |
|
Capital Lease Payments Due in Year 4 |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Capital Lease Payments Due in 2-3 Years |
0.6 |
0.2 |
0.2 |
0.1 |
- |
|
Capital Lease Payments Due in 4-5 Years |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Cap. Lease Pymts. Due in Year 6 & Beyond |
0.0 |
0.0 |
0.0 |
0.0 |
- |
|
Pension Obligation - Domestic |
806.4 |
871.3 |
816.3 |
702.0 |
695.7 |
|
Plan Assets - Domestic |
771.7 |
811.6 |
771.9 |
649.2 |
640.6 |
|
Funded Status - Domestic |
-34.6 |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
|
Total Funded Status |
-34.6 |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
|
Discount Rate - Domestic |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return - Domestic |
0.80% |
1.30% |
0.60% |
0.80% |
0.70% |
|
Prepaid Benefits - Domestic |
0.0 |
0.0 |
3.1 |
2.8 |
3.0 |
|
Accrued Liabilities - Domestic |
-35.5 |
-33.8 |
-32.0 |
-29.1 |
-23.0 |
|
Other Assets, Net - Domestic |
-0.9 |
25.9 |
15.6 |
26.5 |
35.0 |
|
Net Assets Recognized on Balance Sheet |
-36.4 |
-7.9 |
-13.3 |
0.2 |
15.0 |
|
Total Plan Obligations |
806.4 |
871.3 |
816.3 |
702.0 |
695.7 |
|
Total Plan Assets |
771.7 |
811.6 |
771.9 |
649.2 |
640.6 |
|
|
|
Annual Cash
Flows |
|
Financials in:
USD (mil) |
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.797487 |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
|
Auditor |
KPMG AZSA LLC |
Ernst & Young
LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Accounts Receivable |
-111.4 |
29.6 |
89.9 |
-138.5 |
-24.2 |
|
Inventories |
-46.0 |
-23.5 |
-144.8 |
-144.0 |
-247.2 |
|
Accounts Payable |
304.1 |
-24.5 |
-167.2 |
57.1 |
118.9 |
|
Taxes Payable |
17.9 |
24.2 |
-43.3 |
47.5 |
-19.7 |
|
Other Operating Cash Flow |
804.6 |
867.4 |
442.8 |
887.8 |
552.1 |
|
Changes in Working Capital |
969.2 |
873.2 |
177.4 |
709.9 |
379.9 |
|
Cash from Operating Activities |
969.2 |
873.2 |
177.4 |
709.9 |
379.9 |
|
|
|
|
|
|
|
|
Purchase of Fixed Assets |
-188.6 |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
|
Capital Expenditures |
-188.6 |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
|
Sale of Fixed Assets |
0.4 |
0.2 |
1.0 |
3.5 |
4.1 |
|
Sale/Maturity of Investment |
1,979.8 |
1,737.4 |
1,617.8 |
1,470.1 |
1,957.3 |
|
Purchase of Investments |
-2,476.9 |
-1,786.6 |
-1,694.4 |
-1,518.7 |
-1,854.4 |
|
Other Investing Cash Flow |
-1.0 |
0.1 |
0.1 |
0.2 |
0.3 |
|
Other Investing Cash Flow Items, Total |
-497.7 |
-48.9 |
-75.5 |
-44.8 |
107.4 |
|
Cash from Investing Activities |
-686.3 |
-189.9 |
-230.0 |
-216.4 |
-136.6 |
|
|
|
|
|
|
|
|
Other Financing Cash Flow |
-12.3 |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
|
Financing Cash Flow Items |
-12.3 |
-14.4 |
-14.6 |
-16.1 |
-16.0 |
|
Cash Dividends Paid - Common |
-272.9 |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
|
Total Cash Dividends Paid |
-272.9 |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
|
Common Stock, Net |
0.5 |
0.0 |
-0.1 |
-12.0 |
-0.7 |
|
Issuance (Retirement) of Stock, Net |
0.5 |
0.0 |
-0.1 |
-12.0 |
-0.7 |
|
Long Term Debt
Reduction |
- |
- |
- |
0.0 |
-2.9 |
|
Long Term Debt, Net |
- |
- |
- |
0.0 |
-2.9 |
|
Issuance (Retirement) of Debt, Net |
- |
- |
- |
0.0 |
-2.9 |
|
Cash from Financing Activities |
-284.7 |
-308.0 |
-262.6 |
-237.7 |
-177.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
14.0 |
-7.2 |
-18.9 |
-1.4 |
-95.4 |
|
Net Change in Cash |
12.2 |
368.0 |
-334.1 |
254.4 |
-29.7 |
|
|
|
|
|
|
|
|
Net Cash - Beginning Balance |
1,183.9 |
817.4 |
1,076.2 |
754.7 |
713.0 |
|
Net Cash - Ending Balance |
1,196.1 |
1,185.4 |
742.0 |
1,009.2 |
683.3 |
|
Depreciation |
192.1 |
199.5 |
204.8 |
208.3 |
194.2 |
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.797487 |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
|
Auditor |
KPMG AZSA LLC |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Sales |
4,702.3 |
4,562.5 |
4,278.0 |
4,476.7 |
3,112.7 |
|
Rounding adjustment Income Statement |
0.0 |
- |
- |
- |
- |
|
Other operating revenue |
200.3 |
124.2 |
45.0 |
105.1 |
- |
|
Revenue on Patent |
- |
- |
- |
- |
49.3 |
|
Total Revenue |
4,902.7 |
4,686.6 |
4,322.9 |
4,581.8 |
3,162.0 |
|
|
|
|
|
|
|
|
Rounding adjustment Income Statement |
0.0 |
- |
- |
- |
- |
|
Cost of sales |
2,101.9 |
1,976.3 |
1,850.1 |
2,059.9 |
1,228.6 |
|
Other Selling/General/Admin. Expense |
0.0 |
- |
- |
- |
- |
|
Sales promotion expenses |
178.5 |
200.8 |
181.1 |
178.8 |
150.1 |
|
Payrolls & Bonuses |
392.4 |
399.6 |
366.7 |
325.6 |
286.2 |
|
Provision for bonuses |
44.1 |
40.8 |
31.0 |
36.6 |
25.7 |
|
Periodic retirement benefit costs |
33.0 |
30.0 |
30.8 |
29.4 |
16.2 |
|
Research&Development |
690.6 |
700.8 |
623.1 |
590.8 |
514.8 |
|
Other general expenses |
504.5 |
554.9 |
485.6 |
478.2 |
441.9 |
|
Rounding adjustment Income Statement |
0.0 |
- |
- |
- |
- |
|
SP Co-Development Settlement |
- |
- |
- |
0.0 |
-61.3 |
|
Subsidy |
-0.6 |
0.0 |
-0.6 |
0.0 |
-4.8 |
|
SP Restructuring Liquidate Gain |
- |
0.0 |
-5.5 |
0.0 |
- |
|
SP G Extinguishment of tie-in stocks |
- |
- |
0.0 |
-0.3 |
0.0 |
|
SP Impairment Loss |
1.5 |
1.8 |
0.5 |
0.3 |
7.2 |
|
SP Restructuring expenses |
0.1 |
0.9 |
0.0 |
13.1 |
5.2 |
|
SP Periodic retirement benefit costs |
- |
- |
- |
0.0 |
1.0 |
|
SP Provision for environmental measures |
0.0 |
3.5 |
0.0 |
- |
- |
|
SP L on Adjust. for Chan. of Acct. Asset |
0.0 |
12.6 |
0.0 |
- |
- |
|
SP Loss on disaster |
0.0 |
59.3 |
0.0 |
- |
- |
|
Gain On Valuation Of Derivatives |
-16.7 |
- |
- |
- |
- |
|
SP L on valuation of golf club membershi |
0.0 |
0.1 |
0.0 |
- |
- |
|
SP Loss Val Inv.Sec |
0.0 |
2.7 |
0.0 |
0.1 |
0.2 |
|
NOP G on valuation of derivatives |
- |
- |
0.0 |
-78.3 |
0.0 |
|
NOP Loss Retire FixAsset |
3.2 |
8.3 |
2.4 |
2.3 |
3.4 |
|
NOP L on valuation of derivatives |
0.0 |
0.4 |
31.5 |
0.0 |
13.0 |
|
NOP L on abandonment of fixed assets |
1.2 |
2.4 |
1.5 |
- |
- |
|
Total Operating Expense |
3,933.8 |
3,995.2 |
3,598.2 |
3,636.6 |
2,627.2 |
|
|
|
|
|
|
|
|
Foreign Exchange Losses |
-40.1 |
- |
- |
- |
- |
|
SP Gain Sale Assets |
0.0 |
0.0 |
0.2 |
2.8 |
4.1 |
|
SP Gain Sale Inv.Secs. |
- |
0.0 |
1.1 |
0.0 |
- |
|
SP Gain Settlement of Affiliates |
- |
- |
- |
- |
0.0 |
|
SP Loss Sale Fixed Assets |
0.0 |
-0.1 |
0.0 |
0.0 |
-0.1 |
|
SP Loss Sale Inv.Secs. |
-0.1 |
0.0 |
0.0 |
0.0 |
- |
|
NOP Interest Income |
4.5 |
4.8 |
3.6 |
6.9 |
15.6 |
|
NOP Dividend Income |
1.5 |
1.5 |
1.5 |
1.2 |
4.1 |
|
NOP Dividends income of life insurance |
4.3 |
4.3 |
0.0 |
0.0 |
3.2 |
|
NOP Exchange Gain |
0.0 |
7.1 |
10.0 |
0.0 |
60.5 |
|
Other Non-Operating Income (Expense) |
0.0 |
- |
- |
- |
- |
|
NOP Other Income |
10.0 |
11.7 |
12.1 |
14.3 |
12.6 |
|
NOP Interest Expense |
-0.1 |
-0.1 |
0.0 |
-0.2 |
-1.3 |
|
NOP Inventory Loss |
- |
- |
- |
0.0 |
-18.5 |
|
NOP Exchange Loss |
- |
- |
0.0 |
-11.0 |
0.0 |
|
NOP Other Expenses |
-5.1 |
-3.7 |
-4.9 |
-4.0 |
-4.6 |
|
Net Income Before Taxes |
943.9 |
716.9 |
748.3 |
955.1 |
610.4 |
|
|
|
|
|
|
|
|
Income taxes-current |
330.0 |
261.7 |
263.1 |
333.1 |
215.4 |
|
Net Income After Taxes |
613.9 |
455.2 |
485.2 |
622.1 |
394.9 |
|
|
|
|
|
|
|
|
Minority interests in income |
-9.8 |
-13.0 |
-13.2 |
-17.1 |
-15.1 |
|
Net Income Before Extra. Items |
604.1 |
442.2 |
472.0 |
605.0 |
379.8 |
|
Net Income |
604.1 |
442.2 |
472.0 |
605.0 |
379.8 |
|
|
|
|
|
|
|
|
Earning Adjustment |
- |
-0.1 |
0.0 |
-0.1 |
0.0 |
|
Income Available to Com Excl ExtraOrd |
604.1 |
442.1 |
472.0 |
604.9 |
379.7 |
|
|
|
|
|
|
|
|
Income Available to Com Incl ExtraOrd |
604.1 |
442.1 |
472.0 |
604.9 |
379.7 |
|
|
|
|
|
|
|
|
Basic Weighted Average Shares |
544.2 |
544.2 |
544.2 |
544.5 |
544.8 |
|
Basic EPS Excluding ExtraOrdinary Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Basic EPS Including ExtraOrdinary Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Dilution Adjustment |
- |
0.0 |
0.0 |
0.0 |
0.0 |
|
Diluted Net Income |
604.1 |
442.1 |
472.0 |
604.9 |
379.8 |
|
Diluted Weighted Average Shares |
544.5 |
544.4 |
544.3 |
544.6 |
545.0 |
|
Diluted EPS Excluding ExtraOrd Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
Diluted EPS Including ExtraOrd Items |
1.11 |
0.81 |
0.87 |
1.11 |
0.70 |
|
DPS-Common Stock |
0.50 |
0.50 |
0.46 |
0.43 |
0.33 |
|
Gross Dividends - Common Stock |
272.8 |
273.1 |
247.9 |
232.6 |
179.1 |
|
Normalized Income Before Taxes |
932.6 |
808.9 |
777.9 |
889.6 |
588.8 |
|
|
|
|
|
|
|
|
Inc Tax Ex Impact of Sp Items |
326.0 |
295.3 |
273.5 |
310.2 |
207.8 |
|
Normalized Income After Taxes |
606.6 |
513.7 |
504.4 |
579.4 |
381.0 |
|
|
|
|
|
|
|
|
Normalized Inc. Avail to Com. |
596.7 |
500.5 |
491.2 |
562.2 |
365.8 |
|
|
|
|
|
|
|
|
Basic Normalized EPS |
1.10 |
0.92 |
0.90 |
1.03 |
0.67 |
|
Diluted Normalized EPS |
1.10 |
0.92 |
0.90 |
1.03 |
0.67 |
|
Sales promotion expenses |
178.5 |
200.8 |
181.1 |
178.8 |
150.1 |
|
Research&Development |
690.6 |
700.8 |
623.1 |
590.8 |
514.8 |
|
Interest Expense |
0.1 |
0.1 |
0.0 |
0.2 |
1.3 |
|
BC - Depreciation of Fixed Assets |
192.1 |
- |
- |
- |
- |
|
Depreciation |
- |
199.5 |
204.8 |
208.3 |
194.2 |
|
Income taxes-current |
287.5 |
- |
- |
- |
- |
|
Current Tax - Total |
287.5 |
- |
- |
- |
- |
|
Income taxes-deferred |
42.4 |
- |
- |
- |
- |
|
Deferred Tax - Total |
42.4 |
- |
- |
- |
- |
|
Income Tax - Total |
329.9 |
- |
- |
- |
- |
|
Reported Operating Profit |
957.6 |
783.3 |
754.5 |
882.4 |
498.7 |
|
Reported Ordinary Profit |
945.0 |
797.8 |
741.4 |
965.6 |
553.8 |
|
Service Cost |
35.0 |
33.7 |
30.6 |
27.5 |
25.1 |
|
Interest Cost |
18.6 |
18.5 |
16.6 |
15.0 |
13.3 |
|
Expected Return on Plan Assets |
-17.4 |
-18.0 |
-14.9 |
-13.6 |
-13.3 |
|
Actuarial Gains and Losses |
9.4 |
7.3 |
10.2 |
12.2 |
-1.3 |
|
Prior Service Cost |
-4.0 |
-4.4 |
-4.3 |
-5.1 |
-5.8 |
|
Pension Exp. due to Acct. Changes |
- |
- |
- |
- |
1.0 |
|
Retirement Benefit Expenses Nonrecurrent |
0.0 |
- |
- |
- |
- |
|
Additional Retire. Benefits, Nonrecurr. |
- |
0.3 |
- |
0.6 |
- |
|
Domestic Pension Plan Expense |
41.5 |
37.4 |
38.0 |
36.5 |
19.0 |
|
Defined Contribution Expense |
10.8 |
10.6 |
9.5 |
8.6 |
7.3 |
|
Total Pension Expense |
52.3 |
48.0 |
47.5 |
45.1 |
26.3 |
|
Discount Rate(MIN)-Domestic |
2.25% |
- |
- |
- |
- |
|
Discount Rate |
- |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected return on assets(MIN)-Domestic |
0.80% |
- |
- |
- |
- |
|
Expected Rate of Return |
- |
1.30% |
0.60% |
0.80% |
0.70% |
|
|
|
Annual Balance
Sheet |
|
Financials in:
USD (mil) |
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate |
85.870003 |
76.94 |
81.105 |
93.095 |
90.65 |
|
Auditor |
KPMG AZSA LLC |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Cash & Deposit |
1,291.9 |
1,392.8 |
939.7 |
1,149.1 |
780.7 |
|
Notes and accounts receivable-trade |
1,397.4 |
1,441.6 |
1,398.1 |
1,306.3 |
1,196.5 |
|
Short-term investment securities |
1,176.1 |
792.8 |
736.1 |
560.3 |
603.6 |
|
Inventories - merchandise&finished goods |
919.4 |
1,133.9 |
1,102.9 |
770.2 |
680.5 |
|
Inventories - work-in-process |
4.0 |
0.3 |
0.2 |
0.1 |
0.6 |
|
Inventories - raw materials&supplies |
344.6 |
230.3 |
190.1 |
224.8 |
187.4 |
|
Deferred Inc. Tax |
235.4 |
295.6 |
245.7 |
226.2 |
240.9 |
|
Rounding adjustment Assets |
0.0 |
- |
- |
- |
- |
|
Other Cur. Asset |
170.8 |
164.2 |
153.2 |
181.5 |
109.2 |
|
Allow Doubt. Acc. |
-0.1 |
0.0 |
-0.1 |
-0.4 |
-0.7 |
|
Total current assets |
5,539.7 |
5,451.4 |
4,765.8 |
4,418.1 |
3,798.7 |
|
|
|
|
|
|
|
|
Buildings & Structures |
1,458.6 |
1,559.8 |
1,552.0 |
1,333.7 |
1,356.5 |
|
Accumulated depreciation |
-883.9 |
-938.0 |
-932.0 |
-759.8 |
-746.1 |
|
Machinery, equipment and vehicles |
1,034.9 |
1,099.8 |
1,075.1 |
899.6 |
835.5 |
|
Accumulated depreciation(1) |
-854.1 |
-892.8 |
-838.5 |
-662.9 |
-602.6 |
|
Tools, furniture and fixtures |
511.3 |
543.6 |
497.0 |
406.8 |
389.4 |
|
Accumulated depreciation(2) |
-433.5 |
-462.5 |
-416.4 |
-334.1 |
-317.9 |
|
Land |
118.2 |
132.3 |
122.0 |
106.3 |
109.6 |
|
Constr. In Progr. |
5.5 |
35.3 |
24.8 |
16.4 |
60.5 |
|
Other, prop., plants, & equip., gross |
2.2 |
0.8 |
0.6 |
0.2 |
0.0 |
|
Accumulated depreciation(3) |
-1.1 |
-0.3 |
-0.2 |
0.0 |
0.0 |
|
Software |
2.8 |
4.3 |
7.9 |
11.3 |
27.2 |
|
Other Intangible |
17.0 |
21.2 |
21.2 |
23.5 |
7.0 |
|
Other Investment Securities |
71.5 |
- |
- |
- |
- |
|
Investment Secs. |
- |
82.8 |
92.8 |
103.7 |
158.7 |
|
Invt Secs Noncons, Asc, Affd Cos |
0.7 |
- |
- |
- |
- |
|
Investment Secs.-stock |
- |
0.8 |
0.7 |
- |
- |
|
Long-term loans receivable |
1.5 |
0.1 |
0.2 |
0.3 |
0.5 |
|
Other Long Term Assets |
0.0 |
- |
- |
- |
- |
|
Other Total investments and other assets |
0.0 |
- |
- |
- |
- |
|
Deferred tax assets |
149.3 |
182.4 |
184.2 |
156.8 |
134.6 |
|
Other Assets |
105.2 |
115.1 |
108.5 |
88.9 |
69.6 |
|
Allow Doubt Acc. |
-1.7 |
-2.2 |
-2.3 |
-2.4 |
-2.5 |
|
Property/Plant/Equipment, Total - Net |
0.0 |
- |
- |
- |
- |
|
Total Assets |
6,844.3 |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.7 |
|
|
|
|
|
|
|
|
Operating Liabilities |
485.9 |
225.5 |
240.3 |
368.0 |
317.3 |
|
Cur. Corp. Bond |
- |
- |
- |
- |
0.0 |
|
Cur.Convert. Bond |
- |
- |
- |
- |
0.0 |
|
Current lease obligations |
- |
- |
- |
0.1 |
0.0 |
|
Accounts payable-other |
58.5 |
102.5 |
73.2 |
70.9 |
77.8 |
|
Inc. Tax Payable |
138.0 |
184.0 |
45.4 |
237.8 |
125.5 |
|
Deferred Inc. Tax |
- |
- |
- |
- |
0.0 |
|
Consumption taxes payable |
36.6 |
22.0 |
6.5 |
44.7 |
3.0 |
|
Accrued Expenses |
247.0 |
242.9 |
200.1 |
245.9 |
227.8 |
|
Allow for Bonus |
68.1 |
68.6 |
56.6 |
61.6 |
48.5 |
|
Provision for directors'' bonuses |
2.3 |
2.4 |
2.7 |
1.9 |
2.3 |
|
Rounding adjustment Liability |
0.1 |
- |
- |
- |
- |
|
Allowance for loss on disaster |
- |
0.8 |
0.0 |
- |
- |
|
Provision for environmental measures |
- |
0.4 |
0.0 |
- |
- |
|
Sales Discount & Other |
18.6 |
25.8 |
30.0 |
32.7 |
42.5 |
|
Other Cur. Liabs |
12.0 |
19.5 |
18.3 |
15.7 |
21.4 |
|
Total Current Liabilities |
1,067.1 |
894.4 |
672.9 |
1,079.3 |
866.2 |
|
|
|
|
|
|
|
|
Lease obligations |
- |
- |
- |
0.1 |
0.0 |
|
Total Long Term Debt |
- |
- |
- |
0.1 |
0.0 |
|
|
|
|
|
|
|
|
Deferred tax liabilities |
1.3 |
1.4 |
0.0 |
0.0 |
0.0 |
|
Accrued Retire. |
35.5 |
33.8 |
32.0 |
29.1 |
23.0 |
|
Provision for environmental measures |
2.0 |
2.3 |
0.0 |
- |
- |
|
Provision for directors'' retirement ben |
7.5 |
9.5 |
9.0 |
8.2 |
8.5 |
|
Other Long Term Liabilities |
0.0 |
- |
- |
- |
- |
|
Other Liabs. |
23.6 |
25.7 |
8.8 |
20.4 |
0.8 |
|
Minority Inter. |
14.0 |
15.7 |
16.8 |
19.2 |
18.2 |
|
Total Liabilities |
1,151.1 |
982.7 |
739.5 |
1,156.3 |
916.7 |
|
|
|
|
|
|
|
|
Other Equity |
0.0 |
- |
- |
- |
- |
|
Deferred gains or losses on hedges |
1.4 |
- |
- |
- |
- |
|
Common Stock |
849.7 |
948.3 |
899.6 |
783.8 |
804.9 |
|
Capital surplus |
1,080.9 |
1,206.3 |
1,144.4 |
997.0 |
1,023.9 |
|
Retained earnings |
4,261.8 |
4,412.2 |
4,039.7 |
3,308.3 |
2,989.6 |
|
Treasury Stock |
-420.8 |
-471.3 |
-447.0 |
-389.6 |
-388.0 |
|
Valuation difference on available-for-sa |
19.1 |
10.9 |
16.5 |
17.6 |
14.9 |
|
Translation Adj. |
-113.2 |
-168.9 |
-138.7 |
-72.7 |
-87.0 |
|
New Stock Subscription Right |
14.2 |
13.2 |
9.6 |
5.8 |
3.6 |
|
Total Equity |
5,693.2 |
5,950.9 |
5,524.1 |
4,650.0 |
4,362.0 |
|
|
|
|
|
|
|
|
Total Liabilities & Shareholders' Equity |
6,844.3 |
6,933.6 |
6,263.6 |
5,806.3 |
5,278.6 |
|
|
|
|
|
|
|
|
S/O-Common Stock |
544.2 |
544.2 |
544.2 |
544.2 |
544.8 |
|
Total Common Shares Outstanding |
544.2 |
544.2 |
544.2 |
544.2 |
544.8 |
|
T/S-Common Stock |
15.4 |
15.5 |
15.5 |
15.5 |
14.9 |
|
Full-Time Employees |
6,836 |
6,779 |
6,709 |
6,485 |
6,383 |
|
Total Number of Shareholders |
43,909 |
- |
- |
- |
- |
|
Number of Common Shareholders |
- |
49,522 |
50,418 |
55,513 |
44,372 |
|
Division And End Of Current Period Remai |
1.8 |
- |
- |
- |
- |
|
Remaining |
- |
2.0 |
1.8 |
1.6 |
- |
|
Total Long Term Debt, Supplemental |
1.8 |
2.0 |
1.8 |
1.6 |
- |
|
Capital Lease maturing within 1 yr |
0.5 |
0.3 |
0.2 |
0.1 |
- |
|
Cap Lease Maturg over a Yr within 2 Yrs |
0.4 |
- |
- |
- |
- |
|
Capital Lease maturing within 2 yr |
- |
0.2 |
0.1 |
0.0 |
- |
|
Cap Lease Maturg over 2 Yr within 3 Yrs |
0.2 |
- |
- |
- |
- |
|
Capital Lease maturing within 3 yr |
- |
0.0 |
0.0 |
0.0 |
- |
|
Cap Lease Maturg over 3 Yr within 4 Yrs |
0.0 |
- |
- |
- |
- |
|
Capital Lease maturing within 4 yr |
- |
0.0 |
0.0 |
0.0 |
- |
|
Capital lease remaing after 5 years |
0.0 |
- |
- |
- |
- |
|
Remaining |
- |
0.0 |
0.0 |
0.0 |
- |
|
Total Capital Leases, Supplemental |
1.2 |
0.5 |
0.4 |
0.2 |
- |
|
Pension Obligation |
806.4 |
871.3 |
816.3 |
702.0 |
695.7 |
|
Fair Value of Plan Assets |
771.7 |
811.6 |
771.9 |
649.2 |
640.6 |
|
Funded Status |
-34.6 |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
|
Total Funded Status |
-34.6 |
-59.7 |
-44.5 |
-52.8 |
-55.1 |
|
Discount Rate |
2.25% |
2.25% |
2.25% |
2.25% |
2.25% |
|
Expected Rate of Return |
0.80% |
1.30% |
0.60% |
0.80% |
0.70% |
|
Unrecognized Prior Service Cost |
-14.5 |
-20.4 |
-18.1 |
-19.8 |
-25.6 |
|
Unrecognized Actuarial Gains and Losses |
13.6 |
46.3 |
33.7 |
46.3 |
60.7 |
|
Prepaid Pension Benefits |
0.0 |
0.0 |
3.1 |
2.8 |
3.0 |
|
Reserve for Accrued Retirement Benefits |
-35.5 |
-33.8 |
-32.0 |
-29.1 |
-23.0 |
|
Net Assets Recognized on Balance Sheet |
-36.4 |
-7.9 |
-13.3 |
0.2 |
15.0 |
|
|
|
Annual Cash
Flows |
|
Financials in:
USD (mil) |
|
|
31-Dec-2012 |
31-Dec-2011 |
31-Dec-2010 |
31-Dec-2009 |
31-Dec-2008 |
|
Period Length |
12 Months |
12 Months |
12 Months |
12 Months |
12 Months |
|
UpdateType/Date |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
Updated Normal |
|
Filed Currency |
JPY |
JPY |
JPY |
JPY |
JPY |
|
Exchange Rate
(Period Average) |
79.797487 |
79.698224 |
87.789317 |
93.619712 |
103.395546 |
|
Auditor |
KPMG AZSA LLC |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
Ernst &
Young LLP |
|
Auditor Opinion |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
Unqualified |
|
|
|
|
|
|
|
|
Net Income |
943.9 |
716.8 |
748.2 |
955.1 |
610.3 |
|
Depreciation |
192.1 |
199.5 |
204.8 |
208.3 |
194.2 |
|
Impairment Loss |
1.5 |
1.8 |
0.5 |
0.3 |
7.2 |
|
Increase (decrease) in provision for ret |
5.5 |
3.1 |
-1.2 |
6.4 |
-4.9 |
|
Int.& Dividend Inc. |
-6.0 |
-6.3 |
-5.1 |
-8.0 |
-19.7 |
|
Interest Expenses |
0.1 |
0.1 |
0.0 |
0.2 |
1.3 |
|
Loss Retire FixAsset |
3.2 |
8.3 |
2.4 |
2.3 |
3.4 |
|
Loss (gain) on sales of noncurrent asset |
0.0 |
0.1 |
-0.2 |
-2.8 |
-4.0 |
|
Loss (gain) on sales and valuation of in |
0.1 |
2.7 |
-1.0 |
0.1 |
0.2 |
|
Acc.& Note Rcvbl |
-111.4 |
29.6 |
89.9 |
-138.5 |
-24.2 |
|
Decrease (increase) in inventories |
-46.0 |
-23.5 |
-144.8 |
-144.0 |
-247.2 |
|
Increase (decrease) in notes and account |
304.1 |
-24.5 |
-167.2 |
57.1 |
118.9 |
|
Increase (decrease) in accrued consumpti |
17.9 |
24.2 |
-43.3 |
47.5 |
-19.7 |
|
Rounding adjustment Cash flow |
0.0 |
- |
- |
- |
- |
|
Increase (decrease) in cash and cash equ |
0.5 |
- |
- |
- |
- |
|
Other, net |
-7.8 |
29.4 |
-67.7 |
-24.5 |
41.0 |
|
Int.& Dividend Rcv'd |
5.5 |
6.3 |
4.9 |
7.9 |
15.3 |
|
Interest Paid |
-0.1 |
-0.1 |
-0.1 |
-0.2 |
-1.3 |
|
Tax Paid |
-319.6 |
-148.2 |
-442.7 |
-257.2 |
-291.0 |
|
Adjustment |
- |
- |
-0.1 |
- |
- |
|
Loss on disaster |
0.0 |
59.3 |
0.0 |
- |
- |
|
Proceeds from insurance income |
0.0 |
37.2 |
0.0 |
- |
- |
|
Payments for loss on disaster |
-14.3 |
-42.4 |
0.0 |
- |
- |
|
Cash from Operating Activities |
969.2 |
873.2 |
177.4 |
709.9 |
379.9 |
|
|
|
|
|
|
|
|
Time deposit made |
-344.6 |
-281.0 |
-266.1 |
-249.9 |
-1.3 |
|
Time deposit matured |
331.9 |
248.0 |
256.4 |
120.0 |
0.0 |
|
Purchase of short-term investment securi |
-2,130.3 |
-1,505.5 |
-1,428.2 |
-1,262.0 |
-1,814.3 |
|
Proceeds from sales of short-term invest |
1,647.9 |
1,489.4 |
1,343.0 |
1,350.1 |
1,953.7 |
|
Purch.-Invest. Secs. |
-2.0 |
-0.1 |
-0.1 |
-6.7 |
-38.7 |
|
Sale-Invest. Secs. |
0.0 |
0.0 |
18.4 |
0.0 |
3.7 |
|
Capital Expenditures |
-188.6 |
-141.0 |
-154.5 |
-171.6 |
-243.9 |
|
Sale-Fixed Assets |
0.4 |
0.2 |
1.0 |
3.5 |
4.1 |
|
ST Loans, Net |
- |
- |
- |
- |
0.0 |
|
LT Loans, Net |
- |
- |
- |
- |
0.3 |
|
Other, net |
-1.0 |
0.1 |
0.1 |
0.2 |
- |
|
Cash from Investing Activities |
-686.3 |
-189.9 |
-230.0 |
-216.4 |
-136.6 |
|
|
|
|
|
|
|
|
Redemption-Bonds |
- |
- |
- |
0.0 |
-2.9 |
|
Rounding adjustment Cash flow |
0.0 |
- |
- |
- |
- |
|
Net decrease (increase) in treasury stoc |
0.5 |
0.0 |
-0.1 |
-12.0 |
-0.7 |
|
Dividend Paid |
-272.9 |
-293.6 |
-247.9 |
-209.6 |
-158.0 |
|
Dividend Paid-Minor |
-11.7 |
-14.1 |
-14.5 |
-16.0 |
-16.0 |
|
Other, net |
-0.7 |
-0.3 |
-0.1 |
0.0 |
0.0 |
|
Cash from Financing Activities |
-284.7 |
-308.0 |
-262.6 |
-237.7 |
-177.6 |
|
|
|
|
|
|
|
|
Foreign Exchange Effects |
14.0 |
-7.2 |
-18.9 |
-1.4 |
-95.4 |
|
Net increase (decrease) in cash and cash |
12.2 |
368.0 |
-334.1 |
254.4 |
-29.7 |
|
|
|
|
|
|
|
|
Depreciation |
192.1 |
199.5 |
204.8 |
208.3 |
194.2 |
|
Net Cash - Beginning Balance |
1,183.9 |
817.4 |
1,076.2 |
754.7 |
713.0 |
|
Net Cash - Ending Balance |
1,196.1 |
1,185.4 |
742.0 |
1,009.2 |
683.3 |
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Financials in: USD (mil) |
|
|
Except for share items (millions) and per
share items (actual units) |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.59.14 |
|
|
1 |
Rs.90.05 |
|
Euro |
1 |
Rs.77.06 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.